Invention Grant
- Patent Title: (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
-
Application No.: US15911535Application Date: 2018-03-05
-
Publication No.: US10329256B2Publication Date: 2019-06-25
- Inventor: Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Àngeles Estiarte Martinez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Laria
- Applicant: Oryzon Genomics, S.A.
- Applicant Address: ES Madrid
- Assignee: Oryzon Genomics, S.A.
- Current Assignee: Oryzon Genomics, S.A.
- Current Assignee Address: ES Madrid
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Priority: EP11382325 20111020; EP11382331 20111027
- Main IPC: C07D211/58
- IPC: C07D211/58 ; C07D309/04 ; C07D309/14 ; C07D215/42 ; C07D221/20 ; C07D223/12 ; C07D401/04 ; C07D401/12 ; C07D405/12 ; C07D417/12 ; C07D451/04 ; C07D205/04 ; C07D207/09 ; C07D207/14 ; C07D209/96 ; C07D211/26 ; C07D211/56 ; C07D335/02
Abstract:
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Public/Granted literature
- US20180354902A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS Public/Granted day:2018-12-13
Information query
